Zyngenia is focused on developing new classes of biotherapeutics that address the complexity of diseases by simultaneously targeting multiple biological pathways. This game-changing technology surpasses other biological platforms in the creation of innovative and differentiated monoclonal antibody-based therapeutics (called Zybodies™) that combine multi-functionality with the drug-like properties of conventional monoclonal antibodies. This approach has the potential to improve disease intervention with the cost and development paradigm of a single biologic agent.
This technology platform and the resulting programs generate multiple opportunities for discovery and licensing partnerships. Zyngenia is pursuing a select number of discovery partnership opportunities with companies that are interested in applying Zyngenia's technology to develop novel biotherapeutics. The resulting Zybodies would utilize the partner’s own monoclonal antibodies (or antibodies in the public domain) as core scaffolds, together with selected modular recognition domains (MRDs), generated by Zyngenia, that are better able to address disease biology by virtue of multi-specific and multi-valent interactions. These early-stage partnerships could include one or more novel biotherapeutics across a number of different disease areas. Zyngenia is continually mining its peptide libraries for MRDs to targets of therapeutic importance.
Additionally, Zyngenia is interested in discussing licensing opportunities surrounding its proprietary programs, including its TNFα / Ang2 inflammation program and its oncology programs. The TNFα /Ang2 Zybody program targets these two cytokines, which are both critically involved in inflammation. Zyngenia is initially advancing the program, which is approaching Phase 1 studies, for the treatment of ulcerative colitis. Zyngenia's preclinical data strongly suggest its potential superiority to the parent antibody adalimumab. Zyngenia also has a number of early-stage oncology programs with novel biology that make them attractive partnering assets.